HIV and Hepatitis.com Coverage of the
13th Annual Conference on Retroviruses and Opportunistic Infections
February 5 - 8, 2006, Denver, CO

Dosing

Simple Regimens Are Highly Effective in Developing World - 2/28/06

Schering Revives Study of Experimental CCR5 Entry Inhibitor Vicriviroc in Treatment-naïve HIV Patients

Phase 1/ 2 Data Presented on Experimental Integrase Inhibitor GS 9137 from Gilead Sciences

Merck Announces Interim Results from Phase II Study of MK-0518, an Investigational Oral HIV Integrase Inhibitor